Consol, Evergreen Solar, Juniper, Sequenom: U.S. Equity Movers

By Elizabeth Campbell and Whitney Kisling

Sept. 24 (Bloomberg) -- The following companies may have unusual price changes in U.S. trading today. Stock symbols are in parentheses, and share prices are as of 9:40 a.m. in New York.

Makers of alternative-energy equipment gained after the U.S. Senate passed a bill that would extend tax credits on solar power installations through 2016.

Evergreen Solar Inc. (ESLR US), which RBC Capital Markets analyst Stuart Bush raised to ``sector perform,'' rose 9.9 percent to $6.32. Energy Conversion Devices Inc. (ENER US) added 11 percent to $62.79. Akeena Solar Inc. (AKNS US) surged 23 percent to $5.25. SunPower Corp. (SPWR US) rose 8 percent to $94.52.

Consol Energy Inc. (CNX US) slid 10 percent, the most in a week, to $55.95. The second-biggest U.S. coal producer by market value cut its third-quarter production forecast by as much as 18 percent to 15 million tons and said unit costs in the same period will be up to 10 percent higher than the second quarter.

Goldman Sachs Group Inc. (GS US) gained 2.7 percent to $128.44. The bank raised $10 billion from Warren Buffett's Berkshire Hathaway Inc. (BRK/A US) and public investors in a bid to quell concerns that pushed up the Wall Street firm's borrowing costs and hurt its stock.

James River Coal Co. (JRCC US) slid 11 percent to $29.67. The owner of mines in Kentucky and Indiana said it plans to sell 1.5 million shares of common stock. Additional shares may dilute the value of existing stock.

Juniper Networks Inc. (JNPR US) lost 4 percent to $23.25, the lowest since July 24. The second-largest maker of networking equipment was cut to ``underperform'' from ``neutral'' at Merrill Lynch & Co.

MEMC Electric Materials (WFR US) climbed 6.4 percent, the most since Sept. 12, to $30.81. The maker of silicon wafers for computers and telecommunications equipment was raised to ``outperform'' from ``sector perform'' at RBC Capital Markets.

Sequenom Inc. (SQNM US) rose the most since June 4, climbing 21 percent to $24.95. The company said its test to detect Down syndrome before birth correctly identified more than 200 samples in a study.

To contact the reporters on this story: Elizabeth Campbell in New York ecampbell11@bloomberg.net; Whitney Kisling in New York at wkisling@bloomberg.net.